GoAI
Get started
Alpha Tau Medical Ltd logo

Alpha Tau Medical Ltd

DRTS

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$14.92

+$0.56 · +3.90%

Aug 21, 4:00 PM ET

Pre-market

$15.143

+$0.223 · +1.49%

Aug 24, 7:42 AM ET

DRTS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

32

Expensive

Momentum

71

Gaining

Sentiment

50

Mixed

Risk resilience

53

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.

Industry
Biotechnology
Sector
Healthcare
Headquarters
IL
CEO
Uzi Sofer
Listed since
Mar 8, 2021
Employees
121

Market position

Day range

Current $14.92

52-week range

Current $14.92

Open
$14.76
Previous close
$14.36
Volume
626.21K
0.8× average
Average volume
781.97K
Average daily volume
Market cap
1.35B USD
Beta
1.19
Market reference 1
50-day average
$12.359
+20.72% above average
200-day average
$8.2476
+80.90% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
396.63M USD
P/E (TTM)
-14.35×
P/B (TTM)
30.8×
P/S (TTM)
0×
EV / EBITDA
-9.66×
Earnings yield
-10.69%
Free cash flow yield
-8.21%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-55.29%
Return on assets
-40.00%
Return on invested capital
-43.50%

Financial health

Debt / equity
0.34×
Current ratio
7.45×

Financial statements

Income trends

Operating income

−42.29M USD-17.33%

Net income

−42.63M USD-34.26%
Income trends across reported periods43.51M USD12.19M USD−19.13M USD−50.46M USDOperating income, FY2021: −13.79M USDOperating income, FY2022: −32.14M USDOperating income, FY2023: 35.68M USDOperating income, FY2024: −36.04M USDOperating income, FY2025: −42.29M USDNet income, FY2021: −27.27M USDNet income, FY2022: −33.76M USDNet income, FY2023: −29.16M USDNet income, FY2024: −31.75M USDNet income, FY2025: −42.63M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −13.79M USD. Operating income FY2022 −32.14M USD. Operating income FY2023 35.68M USD. Operating income FY2024 −36.04M USD. Operating income FY2025 −42.29M USD. Net income FY2021 −27.27M USD. Net income FY2022 −33.76M USD. Net income FY2023 −29.16M USD. Net income FY2024 −31.75M USD. Net income FY2025 −42.63M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Cost of goods sold1.23M USD1.1M USD1.07M USD979K USD776K USD
Gross profit−1.23M USD−1.1M USD−1.07M USD−979K USD−776K USD
Research and development30.83M USD27.02M USD26.42M USD20.89M USD11.45M USD
Selling, general, and administrative10.22M USD7.92M USD9.26M USD11.25M USD2.34M USD
Operating expenses41.06M USD34.94M USD34.61M USD32.14M USD13.79M USD
Interest income3.84M USD4.28M USD4.76M USD1.79M USD211K USD
Interest expense419K USD344K USD39K USD1.77M USD13.27M USD
Depreciation and amortization1.23M USD1.1M USD1.07M USD979K USD776K USD
Operating income−42.29M USD−36.04M USD35.68M USD−32.14M USD−13.79M USD
Net income−42.63M USD−31.75M USD−29.16M USD−33.76M USD−27.27M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
40%
4 beats, 5 misses, 1 met estimate
Average EPS surprise
-32.72%
10 comparable reports
Latest EPS result
-0.5
Estimate -0.14 · Miss by 254.91%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.1-0.25-0.39-0.54Q1 '25MetQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 12, 2025: actual -0.13, estimate -0.13, surprise 0.00%, Met estimate. Q2 2025, reported May 19, 2025: actual -0.12, estimate -0.14, surprise +14.29%, Beat. Q3 2025, reported Aug 11, 2025: actual -0.13, estimate -0.12, surprise -8.33%, Miss. Q4 2025, reported Nov 20, 2025: actual -0.14, estimate -0.12, surprise -16.67%, Miss. Q1 2026, reported Mar 9, 2026: actual -0.14, estimate -0.13, surprise -7.69%, Miss. Q2 2026, reported May 18, 2026: actual -0.26, estimate -0.13, surprise -100.00%, Miss. Q3 2026, reported Aug 10, 2026: actual -0.5, estimate -0.141, surprise -254.91%, Miss. Q4 2026, reported Nov 19, 2026: actual —, estimate -0.14, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates395.71K270.89K146.07K21.25KQ2 '25EstimateQ1 '26EstimateQ2 '26EstimateQ3 '26MissQ4 '26Estimate
Q2 2025, reported May 19, 2025: actual —, estimate 25K USD, surprise —, Comparison unavailable. Q1 2026, reported Mar 9, 2026: actual —, estimate 63K USD, surprise —, Comparison unavailable. Q2 2026, reported May 18, 2026: actual —, estimate 49.75K USD, surprise —, Comparison unavailable. Q3 2026, reported Aug 10, 2026: actual 100K USD, estimate 144.5K USD, surprise -30.80%, Miss. Q4 2026, reported Nov 19, 2026: actual —, estimate 368.25K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$13.67

8.38% downside
Past 12 months12-month forecastHigh $17.00Average $13.67Low $8.00

Rating distribution

6 ratings
Strong buy00%
Buy583%
Hold117%
Sell00%
Strong sell00%

DRTS peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding DRTS

Funds reporting this stock among their holdings, ordered by reported position size.

ARK Israel Innovative Technology ETF logoARK Israel Innovative Technology ETFIZRL
Market value
2.75M
Weight
2.06%
AUM
136.9M USD
Expense ratio
0.49%
Price / 1D
$29.04+0.87%
Even Herd Long Short ETF logoEven Herd Long Short ETFEHLS
Market value
358.77K
Weight
0.62%
AUM
59.5M USD
Expense ratio
2.62%
Price / 1D
$25.525+0.10%
Avantis Responsible International Equity ETF logoAvantis Responsible International Equity ETFAVSD
Market value
104.02K
Weight
0.03%
AUM
369.1M USD
Expense ratio
0.23%
Price / 1D
$82.994+0.86%

Continue in GoAI

Research DRTS

research.disclaimer